VOYA Investment Management
SYRS

VOYA Investment Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

VOYA Investment Management’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,974
Closed -$47K – 2911
2022
Q1 		$47K Buy
3,974
+1,435
+57% +$25.7K ﹤0.01% 2601
2021
Q4 		$83K Buy
2,539
+271
+12% +$11K ﹤0.01% 2691
2021
Q3 		$101K Hold
2,268
– – ﹤0.01% 2736
2021
Q2 		$124K Buy
2,268
+255
+13% +$15.1K ﹤0.01% 2735
2021
Q1 		$151K Buy
2,013
+98
+5% +$10.2K ﹤0.01% 2601
2020
Q4 		$208K Buy
1,915
+438
+30% +$40K ﹤0.01% 2396
2020
Q3 		$131K Hold
1,477
– – ﹤0.01% 2285
2020
Q2 		$157K Sell
1,477
-382
-21% -$34.3K ﹤0.01% 2236
2020
Q1 		$110K Hold
1,859
– – ﹤0.01% 2320
2019
Q4 		$128K Buy
1,859
+499
+37% +$30.3K ﹤0.01% 2492
2019
Q3 		$141K Hold
1,360
– – ﹤0.01% 2325
2019
Q2 		$126K Buy
1,360
+323
+31% +$22.5K ﹤0.01% 2406
2019
Q1 		$95K Buy
+1,037
New +$72.2K ﹤0.01% 2433

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VOYA Investment Management's SYRS Position: Q2 2022 in Review

VOYA Investment Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2022, closing a stake of 3,974 shares — an estimated $47K sold.

VOYA Investment Management first reported a position in SYRS in Q1 2019 and held it in 13 quarters. The position peaked at $208K in Q4 2020. 67 funds tracked by Wall St. Rank hold SYRS as of Q2 2022.

  • VOYA Investment Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • VOYA Investment Management sold 3,974 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $47K.
  • VOYA Investment Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q1 2019 and held it in 13 quarters.
  • VOYA Investment Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $208K in Q4 2020.
  • 67 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on VOYA Investment Management's 13F filing for Q2 2022, filed 15 Aug 2022.